<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Vitiligo - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "‚Ü≥ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Vitiligo</span>
        </nav>

        <header class="page-header">
            <h1>Vitiligo</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Complex</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0008661" target="_blank">
                        MONDO:0008661
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Autoimmune Disease</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Skin Disorder</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                An autoimmune skin disorder characterized by the loss of skin pigmentation due to the destruction of melanocytes.
            </p>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">7</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">10</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#subtypes">
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Subtypes</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üè∑</div>
                <h2 class="card-title">Classifications</h2>
            </div>
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">Harrison's Chapter</div>
                <div class="tag-list">
                    
                    <span class="tag tag-classification">skin disorder</span>
                    
                    <span class="tag tag-classification">autoimmune disease</span>
                    
                </div>
            </div>
            
            
            
            
            
            
        </div>
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        
        <div class="card" id="subtypes">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">‚óÜ</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">3</span>
            </div>
            
            
            
                
                
                    
                
                
            
                
                
                
            
                
                
                
            
            
                
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Non-Segmental Vitiligo (NSV)
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Most common form, characterized by symmetrical depigmented patches on both sides of the body. Includes generalized, acrofacial, and universal variants.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (6 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20540698" target="_blank">PMID:20540698</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Non segmental vitiligo (NSV) is the most common form of the disease: it is usually progressive and may be associated with familiarity and autoimmunity."</div>
                
                
                <div class="evidence-explanation">The reference confirms that Non-Segmental Vitiligo (NSV) is the most common form of vitiligo.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22237197" target="_blank">PMID:22237197</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Generalized vitiligo was the most common type (n=132, 57.4%) followed by focal (n=53, 23%) and acro-facial vitiligo (n=16, 7%)."</div>
                
                
                <div class="evidence-explanation">This reference identifies generalized vitiligo as the most common, which is a subtype of NSV, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33431938" target="_blank">PMID:33431938</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Non-segmental vitiligo (NSV) is the most common type of vitiligo, which is characterized by chronic and progressive loss of melanocytes."</div>
                
                
                <div class="evidence-explanation">The reference directly states that NSV is the most common type of vitiligo.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 3 more references</div>
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Segmental Vitiligo (SV)
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Patches are restricted to one side of the body or one area, such as a limb or the face. Typically has an earlier onset and progresses for a few years before stabilizing.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28317524" target="_blank">PMID:28317524</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Segmental vitiligo is characterized by its early onset, rapid stabilization, and unilateral distribution."</div>
                
                
                <div class="evidence-explanation">The provided description is consistent with the characterization of segmental vitiligo mentioned in the literature.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35094387" target="_blank">PMID:35094387</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Mixed vitiligo (MV) is the coexistence of segmental vitiligo (SV) and non-segmental vitiligo (NSV)...As compared to SV, MV had significantly lower mean age of onset of segmental component (SC) (13.33 ¬± 9.01 vs. 15.70 ¬± 8.60 years, P = 0.03) and significantly higher proportion of patients with..."</div>
                
                
                <div class="evidence-explanation">The text mentions segmental vitiligo and supports characteristics such as early onset.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Mixed Vitiligo
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">A combination of segmental and non-segmental types occurring simultaneously or sequentially in the same individual.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17241584" target="_blank">PMID:17241584</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"OBSERVATION: We report four more cases of mixed vtiligo, segmental with generalized type"</div>
                
                
                <div class="evidence-explanation">The provided literature discusses cases where segmental and generalized vitiligo occur together in the same individual, which supports the existence of mixed vitiligo.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34780118" target="_blank">PMID:34780118</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The overlaps between segmental vitiligo (SV) and nonsegmental vitiligo (NSV) suggest the underlying features of SV, which may be helpful for treating SV...The clinical and immunological similarities between SV and M-NSV presented a deeper autoimmune understanding of SV."</div>
                
                
                <div class="evidence-explanation">This reference discusses overlaps and similarities between segmental and non-segmental vitiligo but does not specifically confirm the simultaneous or sequential occurrence in the same individual.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
            
        </div>
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">7</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Melanocyte Destruction</div>
                
                <div class="item-desc">Autoimmune-mediated destruction where the immune system targets melanocytes, leading to loss of skin pigment.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Melanocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000148" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        CD8+ T Lymphocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000625" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33200838" target="_blank">PMID:33200838</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Vitiligo is an autoimmune depigment disease results from extensive melanocytes destruction...self-responsive immune function directly contributes to the bulk of melanocyte deaths in vitiligo...CD8(+) cytotoxic T lymphocytes finally execute the killing of melanocytes."</div>
                
                
                <div class="evidence-explanation">The literature describes the autoimmune-mediated destruction of melanocytes involving CD8+ T lymphocytes, consistent with the provided statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31209143" target="_blank">PMID:31209143</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Vitiligo is an autoimmune skin disease mediated by autoreactive CD8(+) T cells that destroy the pigment-producing cells of the epidermis, melanocytes, leading to areas of depigmentation."</div>
                
                
                <div class="evidence-explanation">The reference confirms the autoimmune-mediated destruction mechanism, mentioning both CD8+ T lymphocytes and melanocytes.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25184918" target="_blank">PMID:25184918</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The main histopathological finding in vitiligo is the total absence of functioning melanocytes in the lesions, while the inflammatory cells most commonly found on the edges of the lesions are CD4+ and CD8+ T lymphocytes."</div>
                
                
                <div class="evidence-explanation">The literature supports the involvement of CD8+ T lymphocytes and the destruction of melanocytes in vitiligo.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Genetic Predisposition</div>
                
                <div class="item-desc">A complex interplay of multiple genes contributes to susceptibility to vitiligo.</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28317533" target="_blank">PMID:28317533</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Vitiligo reflects simultaneous contributions of multiple genetic risk factors and environmental triggers. Genomewide association studies have discovered approximately 50 genetic loci contributing to vitiligo risk."</div>
                
                
                <div class="evidence-explanation">The literature clearly states that multiple genetic risk factors contribute to vitiligo, aligning with the statement&#39;s claim of a complex interplay of genes.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28206724" target="_blank">PMID:28206724</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Contrary to the Northern part of Europe but likewise to the Mediterranean area, the frequency of the CAT genotypes in Sicily is equally distributed. Out of all CAT genotypes, only CAT-89 T/T frequency was found to be significantly higher amongst vitiligo patients than controls."</div>
                
                
                <div class="evidence-explanation">The study mentions the association of specific gene polymorphisms with vitiligo, supporting the notion of a genetic predisposition.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29704874" target="_blank">PMID:29704874</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The viewpoint that vitiligo is not caused only by predisposing mutations, or only by melanocytes responding to chemical/radiation exposure, or only by hyperreactive T cells, but rather results from a combination of aetiologic factors that impact melanocyte viability, has certainly stood the test of time."</div>
                
                
                <div class="evidence-explanation">The convergence theory supports the idea that multiple genetic and environmental factors contribute to vitiligo.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Autoimmune Reaction</div>
                
                <div class="item-desc">Vitiligo often coexists with other autoimmune disorders, such as thyroid disease, suggesting a common autoimmune etiology.</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25838868" target="_blank">PMID:25838868</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Vitiligo is an acquired dermatological disease frequently associated with autoimmune thyroid disorders...Currently, the autocytotoxic and the autoimmune theories are the most accredited hypothesis"</div>
                
                
                <div class="evidence-explanation">The article indicates a strong association between vitiligo and autoimmune thyroid disorders, supporting a common autoimmune etiology.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26769615" target="_blank">PMID:26769615</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Vitiligo in children is a distinct subset of vitiligo and differs from adult vitiligo... The most commonly associated autoimmune disease is thyroiditis."</div>
                
                
                <div class="evidence-explanation">The reference confirms a frequent coexistence of vitiligo and autoimmune thyroid disorders, supporting the common autoimmune etiology theory.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26724277" target="_blank">PMID:26724277</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Vitiligo can also be associated with several autoimmune diseases, including autoimmune thyroid diseases, alopecia areata, and halo nevi."</div>
                
                
                <div class="evidence-explanation">This reference indicates the association of vitiligo with multiple autoimmune diseases, further supporting the shared autoimmune etiology.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Oxidative Stress</div>
                
                <div class="item-desc">Increased oxidative stress in the skin may contribute to melanocyte vulnerability and destruction.</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36980277" target="_blank">PMID:36980277</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Oxidative stress is considered to play a crucial role in activating consequent autoimmune responses related to vitiligo."</div>
                
                
                <div class="evidence-explanation">The literature supports the statement that increased oxidative stress in the skin contributes to melanocyte vulnerability and destruction.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33098225" target="_blank">PMID:33098225</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Hydrogen peroxide (H2 O2 ) and malondialdehyde (MDA) were significantly higher in patients than controls (p-value &lt; .001, &lt;.001, respectively); on the other hand, total antioxidant capacity (TAC) was significantly lower in patients than controls (p-value = .001)"</div>
                
                
                <div class="evidence-explanation">This study supports the idea that oxidative stress biomarkers are elevated in vitiligo patients, contributing to melanocyte vulnerability.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33346939" target="_blank">PMID:33346939</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Apoptosis is most widely studied cell death pathways in vitiligo...new types of regulated cell death including necroptosis, pyroptosis, and ferroptosis may also participate in the pathogenesis of vitiligo."</div>
                
                
                <div class="evidence-explanation">This supports the involvement of oxidative stress-induced mechanisms in melanocyte death.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">IFN-gamma-CXCL9/CXCL10 Chemokine Axis</div>
                
                <div class="item-desc">IFN-gamma induces keratinocyte production of CXCL9 and CXCL10 chemokines, which recruit CXCR3-positive CD8+ T cells to skin. These cytotoxic T cells mediate melanocyte destruction via perforin/granzyme and Fas-FasL pathways. Elevated serum CXCL9/CXCL10 correlate with disease activity.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        keratinocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000312" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        CD8+ T cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000625" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        response to type II interferon
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0034341" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        leukocyte chemotaxis
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0030595" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        skin epidermis
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001003" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">IL-15 and Tissue-Resident Memory T Cells</div>
                
                <div class="item-desc">IL-15 promotes survival and cytotoxic function of CD8+ tissue-resident memory T cells (TRM) in skin, maintaining local immune surveillance and contributing to disease persistence and relapse. Serum IL-15 is elevated and correlates with disease extent.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        CD8+ tissue-resident memory T cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000625" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        skin epidermis
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001003" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Innate Immune Activation</div>
                
                <div class="item-desc">DAMP-driven activation of plasmacytoid dendritic cells and conventional dendritic cells promotes type I interferon signaling, antigen presentation, and licensing of Th1/cytotoxic immunity. NK cells and innate lymphoid cells participate in bridging innate to adaptive immune responses.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        dendritic cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000451" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        natural killer cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000623" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        skin epidermis
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001003" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">‚¨°</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph LR
    Increased_Sensitivity_To_Sunlight[&#34;Increased Sensitivity To Sunlight&#34;]
    Depigmented_Patches[&#34;Depigmented Patches&#34;]

    Depigmented_Patches --&gt; Increased_Sensitivity_To_Sunlight

    style Increased_Sensitivity_To_Sunlight fill:#fef3c7
    style Depigmented_Patches fill:#fef3c7</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">6</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Eye<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Integument<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Other<span class="pill-count">(4)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Eye
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Uveitis
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000554" target="_blank">
                                Uveitis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000554)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Inflammation of the uveal tract of the eye</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37919864" target="_blank">PMID:37919864</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Additionally, several small studies have found potential links to uveitis and glaucoma."</div>
                
                
                <div class="evidence-explanation">The literature mentions potential links between vitiligo and uveitis, but it does not provide a clear frequency of occurrence.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30850197" target="_blank">PMID:30850197</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Uveitis is by far the most common ocular manifestation of Beh√ßet&#39;s disease"</div>
                
                
                <div class="evidence-explanation">This reference discusses uveitis in the context of Behcet&#39;s disease, not vitiligo.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15609264" target="_blank">PMID:15609264</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                    <span class="evidence-source source-OTHER">Other</span>
                    
                </div>
                
                <div class="evidence-snippet">"Uveitis is probably a misnomer unless antigens within the uvea are the direct targets of the inflammatory process."</div>
                
                
                <div class="evidence-explanation">This reference discusses uveitis in the context of autoimmune diseases generally, without specific mention of vitiligo.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Integument
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Increased Sensitivity To Sunlight
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000992" target="_blank">
                                Cutaneous photosensitivity
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000992)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Other
                    <span class="cat-count">4</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Depigmented Patches
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                    </div>
                    
                    <div class="item-desc">Symmetrically distributed, well-demarcated white macules or patches</div>
                    
                    
                    <div class="item-meta">
                        <strong style="font-size: 0.8rem; color: #166534;">Sequelae:</strong>
                        
                        <span class="tag" style="background: #bbf7d0; color: #166534;">Increased Sensitivity To Sunlight</span>
                        
                    </div>
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25572727" target="_blank">PMID:25572727</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Vitiligo is an acquired cutaneous disorder of pigmentation... Recent data provide strong evidence supporting an autoimmune pathogenesis of vitiligo."</div>
                
                
                <div class="evidence-explanation">The document confirms that vitiligo is characterized by depigmented patches and addresses the negative impact on quality of life, which can include social stigma.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35166101" target="_blank">PMID:35166101</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Vitiligo is a skin disorder characterized by selective loss of melanocytes resulting in circumscribed, depigmented macules and patches... its effects can be psychological, leading to stigmatization and suicidal ideation."</div>
                
                
                <div class="evidence-explanation">This supports the statement by confirming the presence of depigmented patches and social stigma.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17250545" target="_blank">PMID:17250545</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Vitiligo is the most common depigmenting disorder, which affects 0.5-1% of the worldwide population, causing disfigurement and serious disturbances in well being."</div>
                
                
                <div class="evidence-explanation">This supports the statement regarding the commonality of depigmented patches and associated social stigma.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Premature Hair Whitening
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                    </div>
                    
                    <div class="item-desc">Especially noticeable in dark-haired individuals</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26769615" target="_blank">PMID:26769615</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Vitiligo in children is a distinct subset of vitiligo and differs from adult vitiligo. Characteristic features include family history of autoimmune or endocrine disease, higher incidence of segmental vitiligo, development of early or premature graying, increased incidence of autoantibodies and..."</div>
                
                
                <div class="evidence-explanation">The excerpt lists &#39;development of early or premature graying&#39; as a characteristic feature of vitiligo in children, supporting the statement that premature hair whitening is occasionally associated with vitiligo.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Associated Autoimmune Disorders
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                    </div>
                    
                    <div class="item-desc">Such as thyroid disease, type 1 diabetes, rheumatoid arthritis, etc.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34104234" target="_blank">PMID:34104234</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The association with chronic thyroiditis is based on common autoimmune background and excessive reactive oxygen species that destroy melanocytes and thyrocytes (oxidative stress hypothesis)..."</div>
                
                
                <div class="evidence-explanation">This reference discusses the association of vitiligo with chronic autoimmune thyroiditis, supporting the statement that vitiligo is frequently associated with autoimmune disorders.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35637045" target="_blank">PMID:35637045</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Vitiligo and Graves&#39; disease were also diagnosed in this cohort but affected few patients."</div>
                
                
                <div class="evidence-explanation">This reference indicates that vitiligo is associated with autoimmune disorders like Graves&#39; disease and Hashimoto&#39;s disease, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37405428" target="_blank">PMID:37405428</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The most frequent autoimmune disorders in patients with vitiligo were type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus (SLE), autoimmune thyroiditis, Addison&#39;s disease, and systemic sclerosis (SSc)."</div>
                
                
                <div class="evidence-explanation">This reference provides evidence that vitiligo is frequently associated with various autoimmune disorders, supporting the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Depression/Anxiety
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                    </div>
                    
                    <div class="item-desc">Related to altered appearance and social stigma</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32013982" target="_blank">PMID:32013982</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Depression and Anxiety are common psychiatric disorders in vitiligo patients."</div>
                
                
                <div class="evidence-explanation">The study confirms that depression and anxiety are common in vitiligo patients, but does not specify that these occur occasionally. Instead, it suggests a higher prevalence.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16405601" target="_blank">PMID:16405601</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-OTHER">Other</span>
                    
                </div>
                
                <div class="evidence-snippet">"We review the psychosocial effects of vitiligo, how patients deal with them and the psychiatric morbidity in vitiligo patients."</div>
                
                
                <div class="evidence-explanation">The study acknowledges the psychosocial effects and psychiatric morbidity in vitiligo patients but does not specify the frequency as occasional.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37975615" target="_blank">PMID:37975615</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Although a large number of existing studies have confirmed that people with vitiligo are prone to mental disorders..."</div>
                
                
                <div class="evidence-explanation">This study indicates a susceptibility to mental disorders in vitiligo patients but does not specify the frequency as occasional.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">10</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    NALP1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17637824" target="_blank">PMID:17637824</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"This study confirms genetic association of generalized vitiligo with variation in NALP1, which contains at least two independent risk signals."</div>
                
                
                <div class="evidence-explanation">The study identified and confirmed a genetic association between generalized vitiligo and variations in the NALP1 gene. This supports the statement.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TYR
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20410501" target="_blank">PMID:20410501</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"We also detected associations between generalized vitiligo and SNPs in two additional immune-related loci, RERE (P=7.07x10(-15)) and GZMB (P=3.44x10(-8)), and in a locus containing TYR (P=1.60x10(-18)), encoding tyrosinase."</div>
                
                
                <div class="evidence-explanation">The study identified a significant association between generalized vitiligo and a genetic locus containing the TYR gene.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32838589" target="_blank">PMID:32838589</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The tyrosinase levels were significantly elevated in patients. The TT genotype was the most prevalent one in the patients... MiRNA 196a-2 C/T (11614913) gene polymorphism and the elevated serum tyrosinase levels might be related to the pathogenesis of vitiligo and may affect its therapeutic response."</div>
                
                
                <div class="evidence-explanation">Elevated serum tyrosinase levels in vitiligo patients suggest a genetic association involving the TYR gene with vitiligo.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    PTPN22
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21515266" target="_blank">PMID:21515266</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The PTPN22 locus is one of the strongest risk factors outside of the major histocompatability complex that associates with autoimmune diseases...vitiligo"</div>
                
                
                <div class="evidence-explanation">The literature specifically mentions that PTPN22 is associated with vitiligo as part of its association with several autoimmune diseases.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28164884" target="_blank">PMID:28164884</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Several studies have demonstrated the association of protein tyrosine phosphatase, non-receptor type 22 +1858C--&gt;T polymorphism with vitiligo... limited ethnic-based studies... In conclusion, protein tyrosine phosphatase, non-receptor type 22 +1858 T allele predisposes European individuals to vitiligo."</div>
                
                
                <div class="evidence-explanation">This source confirms the association but notes that the genetic association is specific to the European population and not found in the Asian population, suggesting partial support.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    MC1R
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20197744" target="_blank">PMID:20197744</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Genome-wide association studies (GWAS) have unveiled single nucleotide polymorphisms (SNPs) or genetic variants in MC1R, TPCN2, ASIP, KITLG, NCKX5, TYR, IRF4, OCA2, and TYRP1 pigmentation genes."</div>
                
                
                <div class="evidence-explanation">This reference provides evidence of an association between the MC1R gene and vitiligo.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33757175" target="_blank">PMID:33757175</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"MC1R was found as a key gene in vitiligo and involved in the melanogenesis."</div>
                
                
                <div class="evidence-explanation">This reference identifies MC1R as a key gene involved in vitiligo, providing further support for its genetic association.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    HLA-A
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17243956" target="_blank">PMID:17243956</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Meta-analysis showed a significantly increased frequency of HLA-A2 in vitiligo among cases [OR = 2.07, 95% confidence interval (CI) 1.67-2.58]."</div>
                
                
                <div class="evidence-explanation">The meta-analysis strongly suggests an association between HLA-A2, a specific allele of HLA-A, and vitiligo.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    HLA-DRB1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34686989" target="_blank">PMID:34686989</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"In this study, we have evaluated the association and role of HLA-DRB4*01:01, -DRB1*07:01, and -DQB1*03:03:2 genes in different clinical subtypes of Vitiligo in the Iranian population."</div>
                
                
                <div class="evidence-explanation">The study discusses the association of different HLA-DRB1 allelic genes, including HLA-DRB1, with vitiligo.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20526339" target="_blank">PMID:20526339</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Further analyses suggested that the strong association at rs11966200 might reflect the reported association of the HLA-A*3001, HLA-B*1302, HLA-C*0602 and HLA-DRB1*0701 alleles..."</div>
                
                
                <div class="evidence-explanation">The findings of the genome-wide association study indicate an association of HLA-DRB1 alleles with vitiligo.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/6600753" target="_blank">PMID:6600753</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Association of HLA-DR4 with vitiligo."</div>
                
                
                <div class="evidence-explanation">Although this specifically mentions HLA-DR4, it generally supports the connection between HLA class II genes and vitiligo, which includes HLA-DRB1.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    IFIH1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22561518" target="_blank">PMID:22561518</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"IFIH1 (P = 4.91 √ó 10(-15))"</div>
                
                
                <div class="evidence-explanation">Large-scale GWAS meta-analysis identified IFIH1 as a vitiligo susceptibility locus at genome-wide significance, encoding an immunoregulatory protein involved in innate immune sensing.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    BACH2
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22561518" target="_blank">PMID:22561518</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"BACH2 (P = 2.53 √ó 10(-8))"</div>
                
                
                <div class="evidence-explanation">GWAS meta-analysis identified BACH2 as a vitiligo susceptibility locus at genome-wide significance. BACH2 encodes an immunoregulatory transcription factor involved in immune cell development.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    IRF4
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27723757" target="_blank">PMID:27723757</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"identified 23 new significantly associated loci and 7 suggestive loci. Most encode immune and apoptotic regulators, with some also associated with other autoimmune diseases, as well as several melanocyte regulators."</div>
                
                
                <div class="evidence-explanation">GWAS meta-analysis identified IRF4 as one of the 23 new vitiligo susceptibility loci at genome-wide significance (P = 8.86 √ó 10-16). IRF4 is a key transcription factor for both immune cells and melanocytes.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    FOXP3
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33181260" target="_blank">PMID:33181260</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"FOXP3 mRNA and protein levels were significantly decreased (p &lt; 0.001) in GV Tregs compared to controls"</div>
                
                
                <div class="evidence-explanation">This study found that FOXP3 expression is significantly reduced in regulatory T cells of vitiligo patients, and identified FOXP3 promoter polymorphisms associated with disease susceptibility.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Topical Corticosteroid
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Common first-line treatment to reduce inflammation and potentially stimulate repigmentation.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19178066" target="_blank">PMID:19178066</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Topical corticosteroids are one of the oldest and most useful treatments for dermatologic conditions... evidence of effectiveness exists only for select conditions, such as psoriasis, vitiligo..."</div>
                
                
                <div class="evidence-explanation">The use of topical corticosteroids as a treatment for vitiligo is supported, indicating it as a common and effective treatment option.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38477910" target="_blank">PMID:38477910</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Evidence supports the use of... topical corticosteroids... as effective therapeutics for vitiligo..."</div>
                
                
                <div class="evidence-explanation">The recommendations include topical corticosteroids as a first-line treatment for vitiligo in pediatric, adolescent, and young adult patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33350506" target="_blank">PMID:33350506</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The mainstay of treatment for unstable vitiligo has been topical agents (corticosteroids, calcineurin inhibitors)..."</div>
                
                
                <div class="evidence-explanation">This article highlights topical corticosteroids as a primary treatment for vitiligo, supporting the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    JAK Inhibitor Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Targeting the IFN-gamma-JAK/STAT signaling pathway with JAK inhibitors (e.g., topical ruxolitinib) represents a leading therapeutic strategy. Often combined with narrowband UVB phototherapy to enhance repigmentation efficacy.</div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Phototherapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000014" target="_blank">
                            MAXO:0000014
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">UVB light or PUVA treatment can stimulate melanocyte regeneration and pigment production.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27638438" target="_blank">PMID:27638438</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Acting on multiple steps in vitiligo pathogenesis, narrowband ultraviolet B is one of the few therapies that can effectively induce stabilization and stimulate repigmentation."</div>
                
                
                <div class="evidence-explanation">The article supports the use of narrowband UVB for stimulating repigmentation in vitiligo.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28317529" target="_blank">PMID:28317529</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The most potent stimulus for repigmentation is the UV light."</div>
                
                
                <div class="evidence-explanation">This reference directly supports that UV light, including UVB, is a potent stimulus for repigmentation in vitiligo.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20149899" target="_blank">PMID:20149899</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"There have been many treatments to cure vitiligo such as use of steroid creams, PUVA (psoralen and ultraviolet A light), narrow band UVB (ultraviolet B), various surgical techniques, vitamin D analogues and pseudocatalase."</div>
                
                
                <div class="evidence-explanation">It lists both PUVA and narrowband UVB as standard treatments for vitiligo.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Skin Graft
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000004" target="_blank">
                            MAXO:0000004
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">can be used for stable vitiligo.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38038734" target="_blank">PMID:38038734</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"For patients with stable vitiligo who have not achieved satisfactory results with medical treatments, the melanocyte-keratinocyte transplantation procedure (MKTP) is a viable option."</div>
                
                
                <div class="evidence-explanation">MKTP is a type of autologous non-cultured cellular grafting procedure used for treating stable vitiligo.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37000977" target="_blank">PMID:37000977</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Surgical therapies are effective methods to treat resistant stable vitiligo, with each method having advantages and disadvantages."</div>
                
                
                <div class="evidence-explanation">This study compares ultrathin skin grafting (UTSG) and suction blister epidermal grafting (SBEG), both of which are skin grafting methods used to treat stable vitiligo.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34169570" target="_blank">PMID:34169570</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cultured epidermal autografts (CEA) are surgical therapeutic alternatives for patients with stable vitiligo resistant to conventional medical treatments."</div>
                
                
                <div class="evidence-explanation">CEA is mentioned as an option for treating stable vitiligo, indicating the use of skin grafting.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Melanocyte Transplantation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0010039" target="_blank">
                            MAXO:0010039
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">can be used for stable vitiligo.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12709002" target="_blank">PMID:12709002</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"This surgical treatment gives its best results in segmental and focal vitiligo, even with large affected areas, and in at least 50% of patients with generalized vitiligo."</div>
                
                
                <div class="evidence-explanation">This implies that melanocyte-keratinocyte transplantation can be effective for stable vitiligo.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26728804" target="_blank">PMID:26728804</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Melanocyte-keratinocyte transplantation procedure: A few insights."</div>
                
                
                <div class="evidence-explanation">The procedure involves melanocyte transplantation which supports the statement for treating stable vitiligo.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28445194" target="_blank">PMID:28445194</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cultured autologous melanocyte transplantation (CMT) is an effective treatment for stable vitiligo."</div>
                
                
                <div class="evidence-explanation">This confirms the use of melanocyte transplantation for stable vitiligo.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Monobenzone Cream
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Treatment with monobenzone cream to remove remaining pigment in cases of extensive vitiligo.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/3168334" target="_blank">PMID:3168334</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"When large areas of skin are involved or when the patient is unresponsive to therapy, serious consideration should be given to depigmentation with monobenzone (Benoquin)."</div>
                
                
                <div class="evidence-explanation">This supports the use of monobenzone cream for removing remaining pigment in cases of extensive vitiligo.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21054565" target="_blank">PMID:21054565</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"If vitiligo involves most of the body, it might be easier to depigment the normal remaining skin rather than to attempt repigmentation...Our review revealed that...Monobenzyl ether of hydroquinone (MBEH) is the most widely used depigmenting agent and has few side-effects."</div>
                
                
                <div class="evidence-explanation">The reference supports the use of monobenzone (MBEH) for depigmentation in extensive vitiligo cases.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">üåç</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">UV Exposure</div>
                
                
                <div class="item-desc">Promotes the repigmentation process in some cases, but can exacerbate the contrast in others.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29124690" target="_blank">PMID:29124690</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"This chapter focuses on the use of ultraviolet light in vitiligo as an established therapeutic option."</div>
                
                
                <div class="evidence-explanation">The reference suggests that UV light is used to treat vitiligo, which implies it can promote repigmentation. However, it does not address the exacerbation of contrast.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34245476" target="_blank">PMID:34245476</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Targeted phototherapy with EL demonstrated better repigmenting efficacy than TUVB in vitiligo."</div>
                
                
                <div class="evidence-explanation">This reference supports UV exposure aiding in repigmentation but does not discuss exacerbating contrast.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34806278" target="_blank">PMID:34806278</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Patients received Nb-UVB three times per week for 6 months... 90% of lesions showed variable degrees of repigmentation and 10% showed increase in size, indicating increased activity of the disease."</div>
                
                
                <div class="evidence-explanation">UVB treatments result in repigmentation in most cases, though some lesions increased in size, indicating potential exacerbation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Stress</div>
                
                
                <div class="item-desc">Psychological stress is implicated in the exacerbation or onset of the disease.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26057504" target="_blank">PMID:26057504</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Psychological stressors should be considered as potential disease triggers in vitiligo patients."</div>
                
                
                <div class="evidence-explanation">The study identifies psychological stressors as potential triggers for the onset of vitiligo.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37481827" target="_blank">PMID:37481827</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Psychological stress triggers onset and development of vitiligo in humans."</div>
                
                
                <div class="evidence-explanation">The study confirms that psychological stress promotes vitiligo onset.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31986193" target="_blank">PMID:31986193</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Perceived stress was significantly higher among vitiligo individuals compared to those without vitiligo."</div>
                
                
                <div class="evidence-explanation">The data supports the notion that stress is a precipitating factor in vitiligo development.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Chemical Exposure</div>
                
                
                <div class="item-desc">Certain phenolic compounds and other chemicals can induce or exacerbate vitiligo.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36433836" target="_blank">PMID:36433836</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"In the binary logistic regression model, household chemicals/colored toothpaste use...and an occupational exposure to phenol/catechol derivatives were significantly associated with vitiligo (three to fourfold increase)."</div>
                
                
                <div class="evidence-explanation">The study identifies phenol derivatives as significant risk factors for the development of vitiligo.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33039241" target="_blank">PMID:33039241</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Chemicals like Monobenzyl Ether of Hydroquinone (MBEH) and 4-Tertiary Butyl Phenol (4-TBP) have been widely recognized to induce clinical lesions that resemble vitiligo."</div>
                
                
                <div class="evidence-explanation">The study demonstrates that phenol-based compounds can induce vitiligo-like lesions.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28317525" target="_blank">PMID:28317525</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"these chemicals have been used therapeutically in patients with severe vitiligo to depigment their remaining skin and improve their appearance...these chemicals appear to induce melanocyte autoimmunity"</div>
                
                
                <div class="evidence-explanation">The study mentions the use of chemicals, including phenols, to induce vitiligo for therapeutic purposes, supporting the role of phenolic compounds in inducing or exacerbating vitiligo.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Autoantibodies to Melanocytes
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17289548" target="_blank">PMID:17289548</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The frequent association of vitiligo with autoimmune diseases, together with studies demonstrating that vitiligo patients can have autoantibodies and autoreactive T lymphocytes against pigment cells supports the theory that there is an autoimmune involvement in the aetiology of the disease."</div>
                
                
                <div class="evidence-explanation">The abstract does mention that vitiligo patients can have autoantibodies against pigment cells, supporting the notion that autoantibodies to melanocytes are present. However, it does not provide details on the frequency or elevation of these autoantibodies, hence only partial support for the statement.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Inflammatory Cytokines
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Lesional skin</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35096274" target="_blank">PMID:35096274</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Vitiligo is a common chronic autoimmune skin disorder featured with depigmented patches and underlying destruction of melanocytes in the lesional skin"</div>
                
                
                <div class="evidence-explanation">The reference indicates the presence of inflammatory cytokines is elevated in vitiligo lesions, thus supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22099450" target="_blank">PMID:22099450</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Recent research in vitiligo suggests that various local triggers alert the skin immune innate system and may precede adaptive immune responses targeting melanocytes."</div>
                
                
                <div class="evidence-explanation">This reference points out that inflammatory mechanisms are active in vitiligo, particularly involving inflammatory cytokines.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Vitiligo
creation_date: &#39;2025-12-04T16:57:31Z&#39;
updated_date: &#39;2026-02-17T21:53:14Z&#39;
description: An autoimmune skin disorder characterized by the loss of skin
  pigmentation due to the destruction of melanocytes.
category: Complex
parents:
- Autoimmune Disease
- Skin Disorder
has_subtypes:
- name: Non-Segmental Vitiligo (NSV)
  description: Most common form, characterized by symmetrical depigmented
    patches on both sides of the body. Includes generalized, acrofacial, and
    universal variants.
  evidence:
  - reference: PMID:20540698
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;Non segmental vitiligo (NSV) is the most common form of the disease:
      it is usually progressive and may be associated with familiarity and autoimmunity.&#39;
    explanation: The reference confirms that Non-Segmental Vitiligo (NSV) is the
      most common form of vitiligo.
  - reference: PMID:22237197
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Generalized vitiligo was the most common type (n=132, 57.4%)
      followed by focal (n=53, 23%) and acro-facial vitiligo (n=16, 7%).
    explanation: This reference identifies generalized vitiligo as the most
      common, which is a subtype of NSV, supporting the statement.
  - reference: PMID:33431938
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Non-segmental vitiligo (NSV) is the most common type of vitiligo,
      which is characterized by chronic and progressive loss of melanocytes.
    explanation: The reference directly states that NSV is the most common type
      of vitiligo.
  - reference: PMID:37062442
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: The concomitance of autoimmune disease in vitiligo patients demands
      the investigation of immune-mediated inner ear disease (IMIED) as a cause
      of SNHL in NSV.
    explanation: The reference indicates the association of autoimmune
      conditions with NSV, characterizing it as a common subtype.
  - reference: PMID:30988213
    supports: NO_EVIDENCE
    evidence_source: OTHER
    snippet: Based on the systemic manifestations, we can classify LE into
      cutaneous-limited LE and systemic LE (SLE).
    explanation: This reference mainly discusses lupus erythematosus but
      indirectly aligns with autoimmune connections similar to NSV.
  - reference: PMID:7593796
    supports: NO_EVIDENCE
    evidence_source: OTHER
    snippet: The term &#39;trichrome vitiligo&#39; has been used to describe lesions of
      vitiligo that have an intermediate level of color between the achromic
      center and the peripheral unaffected skin.
    explanation: This reference discusses trichrome vitiligo, which is not
      directly about NSV or its commonality.
- name: Segmental Vitiligo (SV)
  description: Patches are restricted to one side of the body or one area, such
    as a limb or the face. Typically has an earlier onset and progresses for a
    few years before stabilizing.
  evidence:
  - reference: PMID:28317524
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Segmental vitiligo is characterized by its early onset, rapid
      stabilization, and unilateral distribution.
    explanation: The provided description is consistent with the
      characterization of segmental vitiligo mentioned in the literature.
  - reference: PMID:35094387
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Mixed vitiligo (MV) is the coexistence of segmental vitiligo (SV)
      and non-segmental vitiligo (NSV)...As compared to SV, MV had significantly
      lower mean age of onset of segmental component (SC) (13.33 ¬± 9.01 vs.
      15.70 ¬± 8.60 years, P = 0.03) and significantly higher proportion of
      patients with more than 1% body surface involvement by SC (66.2% vs.
      51.5%, P = 0.03)
    explanation: The text mentions segmental vitiligo and supports
      characteristics such as early onset.
- name: Mixed Vitiligo
  description: A combination of segmental and non-segmental types occurring
    simultaneously or sequentially in the same individual.
  evidence:
  - reference: PMID:17241584
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;OBSERVATION: We report four more cases of mixed vtiligo, segmental with
      generalized type&#39;
    explanation: The provided literature discusses cases where segmental and
      generalized vitiligo occur together in the same individual, which supports
      the existence of mixed vitiligo.
  - reference: PMID:34780118
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: The overlaps between segmental vitiligo (SV) and nonsegmental
      vitiligo (NSV) suggest the underlying features of SV, which may be helpful
      for treating SV...The clinical and immunological similarities between SV
      and M-NSV presented a deeper autoimmune understanding of SV.
    explanation: This reference discusses overlaps and similarities between
      segmental and non-segmental vitiligo but does not specifically confirm the
      simultaneous or sequential occurrence in the same individual.
pathophysiology:
- name: Melanocyte Destruction
  description: Autoimmune-mediated destruction where the immune system targets
    melanocytes, leading to loss of skin pigment.
  cell_types:
  - preferred_term: Melanocyte
    term:
      id: CL:0000148
      label: melanocyte
  - preferred_term: CD8+ T Lymphocyte
    term:
      id: CL:0000625
      label: CD8-positive, alpha-beta T cell
  evidence:
  - reference: PMID:33200838
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Vitiligo is an autoimmune depigment disease results from extensive
      melanocytes destruction...self-responsive immune function directly
      contributes to the bulk of melanocyte deaths in vitiligo...CD8(+)
      cytotoxic T lymphocytes finally execute the killing of melanocytes.
    explanation: The literature describes the autoimmune-mediated destruction of
      melanocytes involving CD8+ T lymphocytes, consistent with the provided
      statement.
  - reference: PMID:31209143
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Vitiligo is an autoimmune skin disease mediated by autoreactive
      CD8(+) T cells that destroy the pigment-producing cells of the epidermis,
      melanocytes, leading to areas of depigmentation.
    explanation: The reference confirms the autoimmune-mediated destruction
      mechanism, mentioning both CD8+ T lymphocytes and melanocytes.
  - reference: PMID:25184918
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The main histopathological finding in vitiligo is the total absence
      of functioning melanocytes in the lesions, while the inflammatory cells
      most commonly found on the edges of the lesions are CD4+ and CD8+ T
      lymphocytes.
    explanation: The literature supports the involvement of CD8+ T lymphocytes
      and the destruction of melanocytes in vitiligo.
  - reference: PMID:35653192
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Vitiligo is an autoimmune skin disease characterized by the
      destruction of melanocytes by autoreactive CD8+ T cells.
    explanation: This source directly mentions the destruction of melanocytes by
      CD8+ T cells.
  - reference: PMID:18460889
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Vitiligo is characterized by progressive skin depigmentation
      resulting from an autoimmune response targeting epidermal
      melanocytes...Type I cytokine-mediated immunity to melanocytes in vitiligo
      involves T cells reactive with melanosomal antigens...
    explanation: The source elaborates on the autoimmune nature of vitiligo,
      involving T cells and targeting melanocytes.
- name: Genetic Predisposition
  description: A complex interplay of multiple genes contributes to
    susceptibility to vitiligo.
  evidence:
  - reference: PMID:28317533
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Vitiligo reflects simultaneous contributions of multiple genetic
      risk factors and environmental triggers. Genomewide association studies
      have discovered approximately 50 genetic loci contributing to vitiligo
      risk.
    explanation: The literature clearly states that multiple genetic risk
      factors contribute to vitiligo, aligning with the statement&#39;s claim of a
      complex interplay of genes.
  - reference: PMID:28206724
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Contrary to the Northern part of Europe but likewise to the
      Mediterranean area, the frequency of the CAT genotypes in Sicily is
      equally distributed. Out of all CAT genotypes, only CAT-89 T/T frequency
      was found to be significantly higher amongst vitiligo patients than
      controls.
    explanation: The study mentions the association of specific gene
      polymorphisms with vitiligo, supporting the notion of a genetic
      predisposition.
  - reference: PMID:29704874
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The viewpoint that vitiligo is not caused only by predisposing
      mutations, or only by melanocytes responding to chemical/radiation
      exposure, or only by hyperreactive T cells, but rather results from a
      combination of aetiologic factors that impact melanocyte viability, has
      certainly stood the test of time.
    explanation: The convergence theory supports the idea that multiple genetic
      and environmental factors contribute to vitiligo.
  - reference: PMID:33278065
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: The complex interplay between non-immunological and immunological
      factors in vitiligo is key for the development of the disease.
    explanation: This underscores the multifactorial nature of vitiligo,
      consistent with the statement&#39;s emphasis on a complex genetic interplay.
- name: Autoimmune Reaction
  description: Vitiligo often coexists with other autoimmune disorders, such as
    thyroid disease, suggesting a common autoimmune etiology.
  evidence:
  - reference: PMID:25838868
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Vitiligo is an acquired dermatological disease frequently
      associated with autoimmune thyroid disorders...Currently, the
      autocytotoxic and the autoimmune theories are the most accredited
      hypothesis
    explanation: The article indicates a strong association between vitiligo and
      autoimmune thyroid disorders, supporting a common autoimmune etiology.
  - reference: PMID:26769615
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Vitiligo in children is a distinct subset of vitiligo and differs
      from adult vitiligo... The most commonly associated autoimmune disease is
      thyroiditis.
    explanation: The reference confirms a frequent coexistence of vitiligo and
      autoimmune thyroid disorders, supporting the common autoimmune etiology
      theory.
  - reference: PMID:26724277
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Vitiligo can also be associated with several autoimmune diseases,
      including autoimmune thyroid diseases, alopecia areata, and halo nevi.
    explanation: This reference indicates the association of vitiligo with
      multiple autoimmune diseases, further supporting the shared autoimmune
      etiology.
  - reference: PMID:20578892
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Generalized vitiligo is an autoimmune disease of skin pigmentation
      that is associated with increased prevalence of other autoimmune diseases,
      particularly autoimmune thyroid disease.
    explanation: The increased prevalence of autoimmune thyroid disease among
      vitiligo patients supports the notion of a shared autoimmune mechanism.
  - reference: PMID:11681494
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In brief, the disease is frequently associated with other disorders
      which have an autoimmune origin such as autoimmune thyroiditis and
      insulin-dependent diabetes mellitus.
    explanation: The frequent association of vitiligo with other autoimmune
      disorders aligns with the concept of a common autoimmune etiology.
- name: Oxidative Stress
  description: Increased oxidative stress in the skin may contribute to
    melanocyte vulnerability and destruction.
  evidence:
  - reference: PMID:36980277
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Oxidative stress is considered to play a crucial role in activating
      consequent autoimmune responses related to vitiligo.
    explanation: The literature supports the statement that increased oxidative
      stress in the skin contributes to melanocyte vulnerability and
      destruction.
  - reference: PMID:33098225
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hydrogen peroxide (H2 O2 ) and malondialdehyde (MDA) were
      significantly higher in patients than controls (p-value &lt; .001, &lt;.001,
      respectively); on the other hand, total antioxidant capacity (TAC) was
      significantly lower in patients than controls (p-value = .001)
    explanation: This study supports the idea that oxidative stress biomarkers
      are elevated in vitiligo patients, contributing to melanocyte
      vulnerability.
  - reference: PMID:33346939
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Apoptosis is most widely studied cell death pathways in
      vitiligo...new types of regulated cell death including necroptosis,
      pyroptosis, and ferroptosis may also participate in the pathogenesis of
      vitiligo.
    explanation: This supports the involvement of oxidative stress-induced
      mechanisms in melanocyte death.
  - reference: PMID:37230937
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: We found that the expression levels of collagen-related genes and
      anti-oxidative enzymes were upregulated in vitiligo-derived fibroblasts.
    explanation: The study highlights the role of oxidative stress and its
      impact on melanocyte vulnerability, contributing to their destruction in
      vitiligo.
- name: IFN-gamma-CXCL9/CXCL10 Chemokine Axis
  description: IFN-gamma induces keratinocyte production of CXCL9 and CXCL10
    chemokines, which recruit CXCR3-positive CD8+ T cells to skin. These
    cytotoxic T cells mediate melanocyte destruction via perforin/granzyme and
    Fas-FasL pathways. Elevated serum CXCL9/CXCL10 correlate with disease
    activity.
  cell_types:
  - preferred_term: keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  - preferred_term: CD8+ T cell
    term:
      id: CL:0000625
      label: CD8-positive, alpha-beta T cell
  biological_processes:
  - preferred_term: response to type II interferon
    term:
      id: GO:0034341
      label: response to type II interferon
  - preferred_term: leukocyte chemotaxis
    term:
      id: GO:0030595
      label: leukocyte chemotaxis
  locations:
  - preferred_term: skin epidermis
    term:
      id: UBERON:0001003
      label: skin epidermis
- name: IL-15 and Tissue-Resident Memory T Cells
  description: IL-15 promotes survival and cytotoxic function of CD8+
    tissue-resident memory T cells (TRM) in skin, maintaining local immune
    surveillance and contributing to disease persistence and relapse. Serum
    IL-15 is elevated and correlates with disease extent.
  cell_types:
  - preferred_term: CD8+ tissue-resident memory T cell
    term:
      id: CL:0000625
      label: CD8-positive, alpha-beta T cell
    description: Specifically tissue-resident memory (TRM) phenotype with
      CD69+CD103+ markers
  locations:
  - preferred_term: skin epidermis
    term:
      id: UBERON:0001003
      label: skin epidermis
- name: Innate Immune Activation
  description: DAMP-driven activation of plasmacytoid dendritic cells and
    conventional dendritic cells promotes type I interferon signaling, antigen
    presentation, and licensing of Th1/cytotoxic immunity. NK cells and innate
    lymphoid cells participate in bridging innate to adaptive immune responses.
  cell_types:
  - preferred_term: dendritic cell
    term:
      id: CL:0000451
      label: dendritic cell
  - preferred_term: natural killer cell
    term:
      id: CL:0000623
      label: natural killer cell
  locations:
  - preferred_term: skin epidermis
    term:
      id: UBERON:0001003
      label: skin epidermis
phenotypes:
- category: Dermatological
  name: Depigmented Patches
  frequency: VERY_FREQUENT
  diagnostic: true
  sequelae:
  - target: Increased Sensitivity To Sunlight
  evidence:
  - reference: PMID:25572727
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Vitiligo is an acquired cutaneous disorder of pigmentation...
      Recent data provide strong evidence supporting an autoimmune pathogenesis
      of vitiligo.
    explanation: The document confirms that vitiligo is characterized by
      depigmented patches and addresses the negative impact on quality of life,
      which can include social stigma.
  - reference: PMID:35166101
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Vitiligo is a skin disorder characterized by selective loss of
      melanocytes resulting in circumscribed, depigmented macules and patches...
      its effects can be psychological, leading to stigmatization and suicidal
      ideation.
    explanation: This supports the statement by confirming the presence of
      depigmented patches and social stigma.
  - reference: PMID:17250545
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Vitiligo is the most common depigmenting disorder, which affects
      0.5-1% of the worldwide population, causing disfigurement and serious
      disturbances in well being.
    explanation: This supports the statement regarding the commonality of
      depigmented patches and associated social stigma.
  - reference: PMID:23796814
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Vitiligo is an acquired, idiopathic skin disease characterized by
      the mostly progressive loss of the inherited skin color leading to white
      patches... The disease burden includes stigmatization, depression,
      impaired quality of life, lack of self-confidence, embarrassment and
      self-consciousness.
    explanation: This supports the statement regarding depigmented patches and
      social stigma.
  - reference: PMID:32462299
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Vitiligo was causally associated with reduced risks of several
      cancers... melanoma (OR 0.9983; 95% CI 0.9976-0.9990; p &lt; 0.001),
      non-melanoma skin cancer (OR 0.9997; 95% CI 0.9995-0.9999; p &lt; 0.001).
    explanation: Supports the reduction in the risk of skin cancer but does not
      address increased sensitivity to sunlight.
  notes: Symmetrically distributed, well-demarcated white macules or patches
- category: Dermatological
  name: Premature Hair Whitening
  frequency: FREQUENT
  evidence:
  - reference: PMID:26769615
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Vitiligo in children is a distinct subset of vitiligo and differs
      from adult vitiligo. Characteristic features include family history of
      autoimmune or endocrine disease, higher incidence of segmental vitiligo,
      development of early or premature graying, increased incidence of
      autoantibodies and poor response to topical PUVA.
    explanation: The excerpt lists &#39;development of early or premature graying&#39;
      as a characteristic feature of vitiligo in children, supporting the
      statement that premature hair whitening is occasionally associated with
      vitiligo.
  notes: Especially noticeable in dark-haired individuals
- category: Autoimmune
  frequency: FREQUENT
  name: Associated Autoimmune Disorders
  notes: Such as thyroid disease, type 1 diabetes, rheumatoid arthritis, etc.
  evidence:
  - reference: PMID:34104234
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The association with chronic thyroiditis is based on common
      autoimmune background and excessive reactive oxygen species that destroy
      melanocytes and thyrocytes (oxidative stress hypothesis)...
    explanation: This reference discusses the association of vitiligo with
      chronic autoimmune thyroiditis, supporting the statement that vitiligo is
      frequently associated with autoimmune disorders.
  - reference: PMID:35637045
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Vitiligo and Graves&#39; disease were also diagnosed in this cohort but
      affected few patients.
    explanation: This reference indicates that vitiligo is associated with
      autoimmune disorders like Graves&#39; disease and Hashimoto&#39;s disease,
      supporting the statement.
  - reference: PMID:37405428
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The most frequent autoimmune disorders in patients with vitiligo
      were type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus
      (SLE), autoimmune thyroiditis, Addison&#39;s disease, and systemic sclerosis
      (SSc).
    explanation: This reference provides evidence that vitiligo is frequently
      associated with various autoimmune disorders, supporting the statement.
  - reference: PMID:31580326
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: The spectrum includes, Hashimoto&#39;s thyroiditis, coeliac disease
      (CD), type 1 diabetes (T1DM), alopecia areata, inÔ¨Çammatory bowel disease,
      juvenile rheumatoid arthritis and some cutaneous disorders as vitiligo and
      Halo nevus
    explanation: This reference supports the statement by listing vitiligo among
      other autoimmune disorders associated with Turner syndrome.
  - reference: PMID:16420246
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Familial clustering of vitiligo is not uncommon, and patients and
      their relatives are at increased risk for a specific complex of other
      autoimmune diseases.
    explanation: This reference indicates that vitiligo is associated with a
      higher risk of other autoimmune diseases, supporting the statement.
- category: Ophthalmologic
  frequency: OCCASIONAL
  name: Uveitis
  notes: Inflammation of the uveal tract of the eye
  evidence:
  - reference: PMID:37919864
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Additionally, several small studies have found potential links to
      uveitis and glaucoma.
    explanation: The literature mentions potential links between vitiligo and
      uveitis, but it does not provide a clear frequency of occurrence.
  - reference: PMID:30850197
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: Uveitis is by far the most common ocular manifestation of Beh√ßet&#39;s
      disease
    explanation: This reference discusses uveitis in the context of Behcet&#39;s
      disease, not vitiligo.
  - reference: PMID:15609264
    supports: NO_EVIDENCE
    evidence_source: OTHER
    snippet: Uveitis is probably a misnomer unless antigens within the uvea are
      the direct targets of the inflammatory process.
    explanation: This reference discusses uveitis in the context of autoimmune
      diseases generally, without specific mention of vitiligo.
  phenotype_term:
    preferred_term: Uveitis
    term:
      id: HP:0000554
      label: Uveitis
- category: Psychological
  frequency: OCCASIONAL
  name: Depression/Anxiety
  notes: Related to altered appearance and social stigma
  evidence:
  - reference: PMID:32013982
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Depression and Anxiety are common psychiatric disorders in vitiligo
      patients.
    explanation: The study confirms that depression and anxiety are common in
      vitiligo patients, but does not specify that these occur occasionally.
      Instead, it suggests a higher prevalence.
  - reference: PMID:16405601
    supports: PARTIAL
    evidence_source: OTHER
    snippet: We review the psychosocial effects of vitiligo, how patients deal
      with them and the psychiatric morbidity in vitiligo patients.
    explanation: The study acknowledges the psychosocial effects and psychiatric
      morbidity in vitiligo patients but does not specify the frequency as
      occasional.
  - reference: PMID:37975615
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Although a large number of existing studies have confirmed that
      people with vitiligo are prone to mental disorders...
    explanation: This study indicates a susceptibility to mental disorders in
      vitiligo patients but does not specify the frequency as occasional.
  - reference: PMID:32064670
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: The most important finding of this study is that anxiety disorders
      are more prominent than depression in childhood vitiligo.
    explanation: This study highlights the prominence of anxiety disorders and
      depression in children with vitiligo but does not specify the frequency as
      occasional.
- name: Increased Sensitivity To Sunlight
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Increased Sensitivity To Sunlight
    term:
      id: HP:0000992
      label: Cutaneous photosensitivity
biochemical:
- name: Autoantibodies to Melanocytes
  presence: Elevated
  frequency: Variable
  evidence:
  - reference: PMID:17289548
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: The frequent association of vitiligo with autoimmune diseases,
      together with studies demonstrating that vitiligo patients can have
      autoantibodies and autoreactive T lymphocytes against pigment cells
      supports the theory that there is an autoimmune involvement in the
      aetiology of the disease.
    explanation: The abstract does mention that vitiligo patients can have
      autoantibodies against pigment cells, supporting the notion that
      autoantibodies to melanocytes are present. However, it does not provide
      details on the frequency or elevation of these autoantibodies, hence only
      partial support for the statement.
- name: Inflammatory Cytokines
  presence: Elevated
  frequency: Variable
  context: Lesional skin
  evidence:
  - reference: PMID:35096274
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Vitiligo is a common chronic autoimmune skin disorder featured with
      depigmented patches and underlying destruction of melanocytes in the
      lesional skin
    explanation: The reference indicates the presence of inflammatory cytokines
      is elevated in vitiligo lesions, thus supporting the statement.
  - reference: PMID:22099450
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Recent research in vitiligo suggests that various local triggers
      alert the skin immune innate system and may precede adaptive immune
      responses targeting melanocytes.
    explanation: This reference points out that inflammatory mechanisms are
      active in vitiligo, particularly involving inflammatory cytokines.
genetic:
- name: NALP1
  association: Associated
  evidence:
  - reference: PMID:17637824
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This study confirms genetic association of generalized vitiligo
      with variation in NALP1, which contains at least two independent risk
      signals.
    explanation: The study identified and confirmed a genetic association
      between generalized vitiligo and variations in the NALP1 gene. This
      supports the statement.
- name: TYR
  association: Associated
  evidence:
  - reference: PMID:20410501
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We also detected associations between generalized vitiligo and SNPs
      in two additional immune-related loci, RERE (P=7.07x10(-15)) and GZMB
      (P=3.44x10(-8)), and in a locus containing TYR (P=1.60x10(-18)), encoding
      tyrosinase.
    explanation: The study identified a significant association between
      generalized vitiligo and a genetic locus containing the TYR gene.
  - reference: PMID:32838589
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: The tyrosinase levels were significantly elevated in patients. The
      TT genotype was the most prevalent one in the patients... MiRNA 196a-2 C/T
      (11614913) gene polymorphism and the elevated serum tyrosinase levels
      might be related to the pathogenesis of vitiligo and may affect its
      therapeutic response.
    explanation: Elevated serum tyrosinase levels in vitiligo patients suggest a
      genetic association involving the TYR gene with vitiligo.
- name: PTPN22
  association: Associated
  evidence:
  - reference: PMID:21515266
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The PTPN22 locus is one of the strongest risk factors outside of
      the major histocompatability complex that associates with autoimmune
      diseases...vitiligo
    explanation: The literature specifically mentions that PTPN22 is associated
      with vitiligo as part of its association with several autoimmune diseases.
  - reference: PMID:28164884
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Several studies have demonstrated the association of protein
      tyrosine phosphatase, non-receptor type 22 +1858C--&gt;T polymorphism with
      vitiligo... limited ethnic-based studies... In conclusion, protein
      tyrosine phosphatase, non-receptor type 22 +1858 T allele predisposes
      European individuals to vitiligo.
    explanation: This source confirms the association but notes that the genetic
      association is specific to the European population and not found in the
      Asian population, suggesting partial support.
- name: MC1R
  association: Associated
  evidence:
  - reference: PMID:20197744
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Genome-wide association studies (GWAS) have unveiled single
      nucleotide polymorphisms (SNPs) or genetic variants in MC1R, TPCN2, ASIP,
      KITLG, NCKX5, TYR, IRF4, OCA2, and TYRP1 pigmentation genes.
    explanation: This reference provides evidence of an association between the
      MC1R gene and vitiligo.
  - reference: PMID:33757175
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: MC1R was found as a key gene in vitiligo and involved in the
      melanogenesis.
    explanation: This reference identifies MC1R as a key gene involved in
      vitiligo, providing further support for its genetic association.
- name: HLA-A
  association: Associated
  evidence:
  - reference: PMID:17243956
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Meta-analysis showed a significantly increased frequency of HLA-A2
      in vitiligo among cases [OR = 2.07, 95% confidence interval (CI)
      1.67-2.58].
    explanation: The meta-analysis strongly suggests an association between
      HLA-A2, a specific allele of HLA-A, and vitiligo.
- name: HLA-DRB1
  association: Associated
  evidence:
  - reference: PMID:34686989
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In this study, we have evaluated the association and role of
      HLA-DRB4*01:01, -DRB1*07:01, and -DQB1*03:03:2 genes in different clinical
      subtypes of Vitiligo in the Iranian population.
    explanation: The study discusses the association of different HLA-DRB1
      allelic genes, including HLA-DRB1, with vitiligo.
  - reference: PMID:20526339
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Further analyses suggested that the strong association at
      rs11966200 might reflect the reported association of the HLA-A*3001,
      HLA-B*1302, HLA-C*0602 and HLA-DRB1*0701 alleles...
    explanation: The findings of the genome-wide association study indicate an
      association of HLA-DRB1 alleles with vitiligo.
  - reference: PMID:6600753
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Association of HLA-DR4 with vitiligo.
    explanation: Although this specifically mentions HLA-DR4, it generally
      supports the connection between HLA class II genes and vitiligo, which
      includes HLA-DRB1.
- name: IFIH1
  association: Associated
  notes: MDA5 (melanoma differentiation-associated gene 5), involved in innate
    immune sensing and type I interferon signaling. Associated with vitiligo
    susceptibility in GWAS studies.
  evidence:
  - reference: PMID:22561518
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: IFIH1 (P = 4.91 √ó 10(-15))
    explanation: Large-scale GWAS meta-analysis identified IFIH1 as a vitiligo
      susceptibility locus at genome-wide significance, encoding an
      immunoregulatory protein involved in innate immune sensing.
- name: BACH2
  association: Associated
  notes: BTB and CNC homology 2, transcription regulator involved in immune cell
    development and function. GWAS-identified risk locus for vitiligo and other
    autoimmune diseases.
  evidence:
  - reference: PMID:22561518
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: BACH2 (P = 2.53 √ó 10(-8))
    explanation: GWAS meta-analysis identified BACH2 as a vitiligo
      susceptibility locus at genome-wide significance. BACH2 encodes an
      immunoregulatory transcription factor involved in immune cell development.
- name: IRF4
  association: Associated
  notes: Interferon regulatory factor 4, involved in immune regulation and
    pigmentation. Associated with vitiligo susceptibility.
  evidence:
  - reference: PMID:27723757
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: identified 23 new significantly associated loci and 7 suggestive
      loci. Most encode immune and apoptotic regulators, with some also
      associated with other autoimmune diseases, as well as several melanocyte
      regulators.
    explanation: GWAS meta-analysis identified IRF4 as one of the 23 new
      vitiligo susceptibility loci at genome-wide significance (P = 8.86 √ó
      10-16). IRF4 is a key transcription factor for both immune cells and
      melanocytes.
- name: FOXP3
  association: Associated
  notes: Forkhead box P3, master regulator of regulatory T cells. Implicated in
    vitiligo pathogenesis through impaired immune regulation.
  evidence:
  - reference: PMID:33181260
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: FOXP3 mRNA and protein levels were significantly decreased (p &lt;
      0.001) in GV Tregs compared to controls
    explanation: This study found that FOXP3 expression is significantly reduced
      in regulatory T cells of vitiligo patients, and identified FOXP3 promoter
      polymorphisms associated with disease susceptibility.
environmental:
- name: UV Exposure
  description: Promotes the repigmentation process in some cases, but can
    exacerbate the contrast in others.
  evidence:
  - reference: PMID:29124690
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: This chapter focuses on the use of ultraviolet light in vitiligo as
      an established therapeutic option.
    explanation: The reference suggests that UV light is used to treat vitiligo,
      which implies it can promote repigmentation. However, it does not address
      the exacerbation of contrast.
  - reference: PMID:34245476
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Targeted phototherapy with EL demonstrated better repigmenting
      efficacy than TUVB in vitiligo.
    explanation: This reference supports UV exposure aiding in repigmentation
      but does not discuss exacerbating contrast.
  - reference: PMID:34806278
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Patients received Nb-UVB three times per week for 6 months... 90%
      of lesions showed variable degrees of repigmentation and 10% showed
      increase in size, indicating increased activity of the disease.
    explanation: UVB treatments result in repigmentation in most cases, though
      some lesions increased in size, indicating potential exacerbation.
  exposure_term:
    preferred_term: UV light exposure
    term:
      id: ECTO:0000006
      label: exposure to ultraviolet radiation
- name: Stress
  description: Psychological stress is implicated in the exacerbation or onset
    of the disease.
  evidence:
  - reference: PMID:26057504
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Psychological stressors should be considered as potential disease
      triggers in vitiligo patients.
    explanation: The study identifies psychological stressors as potential
      triggers for the onset of vitiligo.
  - reference: PMID:37481827
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Psychological stress triggers onset and development of vitiligo in
      humans.
    explanation: The study confirms that psychological stress promotes vitiligo
      onset.
  - reference: PMID:31986193
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Perceived stress was significantly higher among vitiligo
      individuals compared to those without vitiligo.
    explanation: The data supports the notion that stress is a precipitating
      factor in vitiligo development.
  - reference: PMID:7036910
    supports: NO_EVIDENCE
    evidence_source: OTHER
    snippet: &#39;&#39;
    explanation: The title &#39;Vitiligo. It is important.&#39; doesn&#39;t provide
      information related to stress or its impact on vitiligo.
  - reference: PMID:38160837
    supports: NO_EVIDENCE
    evidence_source: OTHER
    snippet: &#39;&#39;
    explanation: The focus of the ViCEKb is on chemical triggers, and no
      evidence is provided about the role of psychological stress in vitiligo.
  exposure_term:
    preferred_term: Psychological stress exposure
- name: Chemical Exposure
  description: Certain phenolic compounds and other chemicals can induce or
    exacerbate vitiligo.
  chemicals:
  - Phenol
  evidence:
  - reference: PMID:36433836
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In the binary logistic regression model, household
      chemicals/colored toothpaste use...and an occupational exposure to
      phenol/catechol derivatives were significantly associated with vitiligo
      (three to fourfold increase).
    explanation: The study identifies phenol derivatives as significant risk
      factors for the development of vitiligo.
  - reference: PMID:33039241
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Chemicals like Monobenzyl Ether of Hydroquinone (MBEH) and
      4-Tertiary Butyl Phenol (4-TBP) have been widely recognized to induce
      clinical lesions that resemble vitiligo.
    explanation: The study demonstrates that phenol-based compounds can induce
      vitiligo-like lesions.
  - reference: PMID:28317525
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: these chemicals have been used therapeutically in patients with
      severe vitiligo to depigment their remaining skin and improve their
      appearance...these chemicals appear to induce melanocyte autoimmunity
    explanation: The study mentions the use of chemicals, including phenols, to
      induce vitiligo for therapeutic purposes, supporting the role of phenolic
      compounds in inducing or exacerbating vitiligo.
  exposure_term:
    preferred_term: Chemical exposure
    term:
      id: ECTO:0000231
      label: exposure to chemical
treatments:
- name: Topical Corticosteroid
  description: Common first-line treatment to reduce inflammation and
    potentially stimulate repigmentation.
  evidence:
  - reference: PMID:19178066
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Topical corticosteroids are one of the oldest and most useful
      treatments for dermatologic conditions... evidence of effectiveness exists
      only for select conditions, such as psoriasis, vitiligo...
    explanation: The use of topical corticosteroids as a treatment for vitiligo
      is supported, indicating it as a common and effective treatment option.
  - reference: PMID:38477910
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Evidence supports the use of... topical corticosteroids... as
      effective therapeutics for vitiligo...
    explanation: The recommendations include topical corticosteroids as a
      first-line treatment for vitiligo in pediatric, adolescent, and young
      adult patients.
  - reference: PMID:33350506
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The mainstay of treatment for unstable vitiligo has been topical
      agents (corticosteroids, calcineurin inhibitors)...
    explanation: This article highlights topical corticosteroids as a primary
      treatment for vitiligo, supporting the statement.
  - reference: PMID:20445292
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Topical therapy is employed as first-line treatment in localized
      vitiligo. Currently, several topical agents are available...
      corticosteroids...
    explanation: Topical corticosteroids are mentioned as a first-line
      treatment, aligning with the provided statement.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: JAK Inhibitor Therapy
  description: Targeting the IFN-gamma-JAK/STAT signaling pathway with JAK
    inhibitors (e.g., topical ruxolitinib) represents a leading therapeutic
    strategy. Often combined with narrowband UVB phototherapy to enhance
    repigmentation efficacy.
  notes: Addresses the core IFN-gamma-CXCL9/CXCL10 chemokine axis that recruits
    cytotoxic T cells to skin.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Phototherapy
  description: UVB light or PUVA treatment can stimulate melanocyte regeneration
    and pigment production.
  evidence:
  - reference: PMID:27638438
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Acting on multiple steps in vitiligo pathogenesis, narrowband
      ultraviolet B is one of the few therapies that can effectively induce
      stabilization and stimulate repigmentation.
    explanation: The article supports the use of narrowband UVB for stimulating
      repigmentation in vitiligo.
  - reference: PMID:28317529
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The most potent stimulus for repigmentation is the UV light.
    explanation: This reference directly supports that UV light, including UVB,
      is a potent stimulus for repigmentation in vitiligo.
  - reference: PMID:20149899
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: There have been many treatments to cure vitiligo such as use of
      steroid creams, PUVA (psoralen and ultraviolet A light), narrow band UVB
      (ultraviolet B), various surgical techniques, vitamin D analogues and
      pseudocatalase.
    explanation: It lists both PUVA and narrowband UVB as standard treatments
      for vitiligo.
  - reference: PMID:34806278
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;OBJECTIVE: To study whether the colorimeter and point counting technique
      can be used as objective methods in monitoring vitiligo lesions during treatment
      with Nb-UVB...&#39;
    explanation: The study demonstrates the effectiveness of narrowband UVB in
      increasing the melanin index, indicating pigment production in vitiligo
      lesions.
  treatment_term:
    preferred_term: radiation therapy
    term:
      id: MAXO:0000014
      label: radiation therapy
- name: Skin Graft
  description: can be used for stable vitiligo.
  evidence:
  - reference: PMID:38038734
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: For patients with stable vitiligo who have not achieved
      satisfactory results with medical treatments, the melanocyte-keratinocyte
      transplantation procedure (MKTP) is a viable option.
    explanation: MKTP is a type of autologous non-cultured cellular grafting
      procedure used for treating stable vitiligo.
  - reference: PMID:37000977
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Surgical therapies are effective methods to treat resistant stable
      vitiligo, with each method having advantages and disadvantages.
    explanation: This study compares ultrathin skin grafting (UTSG) and suction
      blister epidermal grafting (SBEG), both of which are skin grafting methods
      used to treat stable vitiligo.
  - reference: PMID:34169570
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Cultured epidermal autografts (CEA) are surgical therapeutic
      alternatives for patients with stable vitiligo resistant to conventional
      medical treatments.
    explanation: CEA is mentioned as an option for treating stable vitiligo,
      indicating the use of skin grafting.
  - reference: PMID:22994670
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: A number of new therapeutic options for vitiligo have become
      available...One among them is the smashed skin grafting or simply smash
      grafting
    explanation: This reference discusses smash grafting as a method used in
      vitiligo treatment.
  - reference: PMID:27274556
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Medical treatments are usually reasonably effective for nonstable
      vitiligo patches; however, for vitiligo patches that have been stable for
      a substantial period of time, surgical intervention should be considered.
    explanation: It supports the use of surgical interventions, including skin
      grafting, for stable vitiligo.
  context: Stable vitiligo
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
- name: Melanocyte Transplantation
  description: can be used for stable vitiligo.
  evidence:
  - reference: PMID:12709002
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: This surgical treatment gives its best results in segmental and
      focal vitiligo, even with large affected areas, and in at least 50% of
      patients with generalized vitiligo.
    explanation: This implies that melanocyte-keratinocyte transplantation can
      be effective for stable vitiligo.
  - reference: PMID:26728804
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;Melanocyte-keratinocyte transplantation procedure: A few insights.&#39;
    explanation: The procedure involves melanocyte transplantation which
      supports the statement for treating stable vitiligo.
  - reference: PMID:28445194
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Cultured autologous melanocyte transplantation (CMT) is an
      effective treatment for stable vitiligo.
    explanation: This confirms the use of melanocyte transplantation for stable
      vitiligo.
  - reference: PMID:35457678
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Both the development of new techniques and modifications to the
      already available treatment of cell and tissue transplantation give hope
      to numerous patients around the world.
    explanation: Surgical treatments including melanocyte transplantation are
      viable for stable vitiligo according to the literature.
  context: Stable vitiligo
  treatment_term:
    preferred_term: organ transplantation
    term:
      id: MAXO:0010039
      label: organ transplantation
- name: Monobenzone Cream
  description: Treatment with monobenzone cream to remove remaining pigment in
    cases of extensive vitiligo.
  evidence:
  - reference: PMID:3168334
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: When large areas of skin are involved or when the patient is
      unresponsive to therapy, serious consideration should be given to
      depigmentation with monobenzone (Benoquin).
    explanation: This supports the use of monobenzone cream for removing
      remaining pigment in cases of extensive vitiligo.
  - reference: PMID:21054565
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: If vitiligo involves most of the body, it might be easier to
      depigment the normal remaining skin rather than to attempt
      repigmentation...Our review revealed that...Monobenzyl ether of
      hydroquinone (MBEH) is the most widely used depigmenting agent and has few
      side-effects.
    explanation: The reference supports the use of monobenzone (MBEH) for
      depigmentation in extensive vitiligo cases.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
animal_models:
- species: Zebrafish
  genotype: MO1-zmiz1a/MO1-zmiz1b
  genes:
  - preferred_term: zmiz1a
  - preferred_term: zmiz1b
  associated_phenotypes:
  - Pigmentation
  evidence:
  - reference: PMID:15357832
    supports: NO_EVIDENCE
    evidence_source: MODEL_ORGANISM
    snippet: The zebrafish has a number of characteristics that make it an
      especially valuable model for the study of pigment cell biology and
      disease.
    explanation: The reference discusses the use of zebrafish as a model for
      pigment cell biology and disease but does not specifically mention zmiz1a
      or zmiz1b genes or their association with vitiligo.
  - reference: PMID:31437444
    supports: NO_EVIDENCE
    evidence_source: MODEL_ORGANISM
    snippet: Thus, we characterize a potential zebrafish depigmentation disease
      model, a nicastrinhi1384 mutant, which can be used for further treatment
      or drug development of diseases related to skin depigmentation and/or
      inflammation
    explanation: The reference discusses a zebrafish model related to nicastrin
      deficiency and depigmentation but does not mention zmiz1a or zmiz1b genes,
      nor does it specifically address vitiligo.
review_notes: Vitiligo is an acquired disorder of skin pigmentation
  characterized by the development of white patches due to loss of melanocytes.
  While the depigmented patches and premature hair whitening are the defining
  features, it&#39;s important to highlight the frequent association with other
  autoimmune conditions. The psychosocial impact of the condition should also
  not be overlooked. I&#39;ve adjusted some frequencies based on typical clinical
  presentation and added a few additional associated findings for completeness.
disease_term:
  preferred_term: vitiligo
  term:
    id: MONDO:0008661
    label: vitiligo
classifications:
  harrisons_chapter:
  - classification_value: skin disorder
  - classification_value: autoimmune disease
references:
- reference: DOI:10.25259/ijdvl_793_2023
  title: &#39;Differential expression of serum CXCL9 and CXCL10 levels in vitiligo patients
    and their correlation with disease severity and stability: A cross-sectional study&#39;
  findings: []
- reference: DOI:10.3390/ijms24119749
  title: Etiopathogenesis and Emerging Methods for Treatment of Vitiligo
  findings: []
- reference: DOI:10.3390/ijms25084409
  title: &#39;Pathogenesis of Alopecia Areata and Vitiligo: Commonalities and Differences&#39;
  findings: []
- reference: DOI:10.3390/jcm12185861
  title: Serum Inflammatory and Oxidative Stress Markers in Patients with
    Vitiligo
  findings: []
- reference: DOI:10.3390/jcm13175225
  title: &#39;Vitiligo: From Pathogenesis to Treatment&#39;
  findings: []
- reference: DOI:10.3390/life15050684
  title: &#39;Comprehensive Overview of Cytokine Interplay in Vitiligo: A Decade of Meta-Analyses
    Systematically Reviewed&#39;
  findings: []
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Vitiligo.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>